winningstreak
14 Jul 2017
Re: Share dilution Games - After your sales of AZN and GSK you will have cash-funds to invest, have a look at INSE for great growth potential as well a good dividends, aswell as, in my view, being jolly sound and quite safe. Good luck,ws
gamesinvestor
13 Jul 2017
Re: Share dilution well it looks a little safer than Astra and GSK this morning -- I'm glad to be out of both with a good profit and hopefully away from a substantial big downside if AZN's new drug doesn't work -- it's ominous that Sorryhat is leaving, if true, at a time when it should be imminent glory.Perhaps he sees it failing and he'll then look like a chump for turning down the Pfizer deal.Selling GSK for me was more to do with the declining ROCE over 5 years and the fact that the full effect of the recent off patent big drugs have still to take effect whilst new stuff is going to find it hard to be sufficient in terms of replacement business.Games
winningstreak
13 Jul 2017
Re: Share dilution Games - This is not an exciting EPS-growth company, i.e. not a race horsebut a steady work horse. I think the shares price is nonetheless too low,should be be trading well above 55p, I would say 60p no less. There is avery useful dividend, which is growing year by year. I consider my investment here safe, safe from economic downturns / global market upheavals.IMHO,ws
winningstreak
13 Jul 2017
Re: Sales Games - Interesting report by Hardman, thanks. The share price, off-late, hoversbetween 51p and 53p. I wouldn't read too much into a one day's fall, as often theBuy price of the previous day is compared (by the computer) with the Sellprice of next morning, that in itself showing rises and falls which do not exist.Cheers,ws
gamesinvestor
13 Jul 2017
Share dilution Winning -- One thing noted in reading the report is the heavy share dilution in the expansionary phase over the last years.In 2014 there were 264M shares in Issue and this has risen to 473M to this year. The net effect is that the earnings per share has not grown at all in the last 3 years.The projection into 2019 is that this dilution will stop and the underlying EPS should grow significantly.Any comments on this?The rest of the report reads well and the prospect of Diclectin becoming up to a £40M contributor, whilst there are risks, don't seem to appear in the share price today.The ROIC seems modest at sub 10% but it does seem to be consistent.What's your assessment here - fair value, cheap, or very cheap?Games
gamesinvestor
13 Jul 2017
Re: Sales winning -- started to get plugged into this.The share price is down 4.72% this morning, I think partly in sympathy with all the pharma companies getting hit on the back of SorryHat leaving Astra.I'm just reading this report which so far reads encouragingly :-[link]
winningstreak
11 Jul 2017
Re: Sales The good news is that the share price has not been affected bythose sales, indeed the share price has gone up. Clearly for every sale there was a buyer, and when a buyer's holding has not gone above 3% no declaration needs to be made.IMHO,ws
gamesinvestor
11 Jul 2017
Sales [link] down the news items there are many organisations and individuals selling big chunks over the last weeks.Games
bigmacone
04 Jul 2017
21,000,000 Shares Sold - To Whom? That's 21 million shares sold in the second half of June but no corresponding buy RNS. Where are they all going?
Ozonechemist
01 Jun 2017
Re: Cheap, cheap, cheap. If this increase in share price keeps up, our dividends yield will look meager in comparison, despite it's 10% y-o-y increase.
Ozonechemist
01 Jun 2017
Re: Going Forward Unless the factory shuts down, like what happened to Ashton & Parson's a few years back. Thanks
claude reins
01 Jun 2017
Re: Cheap, cheap, cheap. Should have lsitened to you. You didnt havee to wait for 6 months.
Oxtrader
31 May 2017
Re: Going Forward The latter, at least in the management's eyes & rightly so. Build a portfolio in a sustainable manner. However it'll take a couple of years for this latest acquisition to pay off for itself. But these type of products don't fluctuate often, so sitting tight for now.
Ozonechemist
31 May 2017
Going Forward What do we see going forward for APH? We have a yearly growing dividend (albeit teeny increments), LOTS of cash and good growing demand for products.What are the chances for:- Alliance being an acquisition target- A share buyback to decrease the number of shares and being able to offer a bigger dividend/share?- Nothing and keep buying more brandsThanks,OC
winningstreak
04 May 2017
Re: Cheap, cheap, cheap. Claude - Your thoughts are the same as mine - where did these sharesgo? If the purchasers (could be a few) did not increase or create a holdingabove 3% then no announcement needs to be made. So I am assumingthis (below 3%) being the case.Cheers,ws
